The company incurred a loss in its most recent quarterly results.

Douglas Lankler "executed key business development transactions to strengthen Pfizer's obesity and cancer drug pipeline," the company said in its newly filed proxy statement.

Pfizer is ramping up plans for tilrekimig after a phase 2 win raised hopes that the once-monthly trispecific antibody could hold its own against approved eczema drugs. | Pfizer is ramping up plans for ...

By Padmanabhan Ananthan March 9 (Reuters) - U.S. drugmaker Pfizer said on Monday its experimental drug for a chronic skin ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...

By Andrew Silver SHANGHAI, March 6 (Reuters) - China has approved Pfizer's GLP-1 treatment Xianweiying for long-term weight ...

If you are wondering whether Pfizer's current share price reflects its long term potential or lingering concerns, looking closely at what you are paying for each dollar of its business is a useful ...

Pfizer , Teva and other major drugmakers have failed to persuade a federal judge to disqualify a former prosecutor who is representing private health insurers suing the ​companies after he spearheaded ...

These companies' shares have fallen too far, offering investors an attractive opportunity.

This darling of the Covid era has given back considerable gains in recent years, but it could be on the verge of a turnaround ...